cyrilzakka/clinical-trials huggingface dataset:
Unobtrusive Sensing of Medication Intake ("USE-MI")

The purpose of this study is to test the USE-MI system hardware and software to see if it can accurately measure when subjects take their HIV-related medications and help them remember to take these medications. With the use of a smartwatch and smartphone "app", investigators hope to be able to monitor medication adherence in real-time and send subjects electronic reminders when they may have forgotten to take their medication.

Human immunodeficiency virus (HIV) treatment is most likely to be successful when patients are committed to taking their medications as prescribed (medication adherence). For maximum benefit, researchers found that patients receiving antiretroviral therapy (ART) to treat HIV infection and pre-exposure prophylaxis (PrEP) to prevent HIV infection have need consistent, high levels of adherence for maximum benefit. However, some patients struggle to take their HIV-related medications regularly and that can lead to losing on the benefits the medication can provide - either suppressing the HIV infection so people do not get sick from it or transmit it, or failing to prevent infection when someone is exposed.

Objectives: Conduct an evaluation of USE-MI to assess accuracy, robustness, acceptability of the system.

All subjects will continue to take their ART or PrEP medication as prescribed by their regular doctor. The USE-MI system is being developed as a behavioral intervention to enhance medication adherence. In the pilot phase, the investigators plan to enroll 10 subjects to use the USE-MI system for 1 month to get initial feedback about the system. In the second phase, up to 50 subjects will begin using the USE-MI for up to 6 months to assess accuracy, robustness and acceptability of the system.

Eligibility Criteria:
Inclusion Criteria:

* Either a) have an HIV infection and are taking ART, or b) risk factors for contracting HIV infection and are taking PrEP
* Taking their medications from pill bottles, or other containers that the USE-MI system can monitor properly
* Reasonable proficiency in English
* Able to come to the research office for monthly follow-up visits

Exclusion Criteria:

* Not responsible for taking their own HIV medications (e.g. residing in a supervised setting where their medications are administered to them)
* Taking medications using a method that the USE-MI system cannot monitor properly
* Lacking proficiency in English
Gabapentin Premedication to Reduce Postoperative Pain for Pediatric Tonsillectomy

The purpose of this pilot study: 1) to examine the use of gabapentin in reducing pain in the first 48 hours postoperatively including the total amount of narcotics mg/kg given 2) to record the time to first analgesic postoperatively and 3) to compare Wong Baker and the 0-10 numeric pain distress scale scores at 12, 24 and 48 hours postoperatively. We hypothesize one 15mg/kg (up to 600mg) dose of gabapentin will decrease mean narcotic amounts in mg/kg compared to participants who do not receive preoperative gabapentin and will demonstrate a decreased mean time to first analgesic as well as to lower mean pain scores for each age group at 12, 24 and 48 hours.

This double blinded randomized control trial will enroll 50 children age 3-18 years, undergoing T/As from a regional healthcare organization. Patients will be receiving either one gabapentin dose (15mg/kg up to 600mg) or placebo preoperatively. Both control and test group will receive the standard narcotic regimen intraoperatively. Additionally, young children will receive instruction for Tylenol and Motrin postoperatively while teenagers will receive a narcotic prescription. Outcome measurements include: mean Tylenol mg/kg, Motrin mg/kg and narcotic mg/kg use. Additional measurements: Mean time to first analgesic. Phone interviews with the research nurse for three days postoperatively will elicit pain scores at 12, 24 and 48 hours postoperatively.

Eligibility Criteria:
Inclusion Criteria:

* participants age 3-18 years
* ASA class 1 or 2
* elective Tonsillectomy/Adenoidectomy
* outpatient setting.

Exclusion Criteria:

* BMI \>40kg/m2
* history of renal insufficiency, chronic pain
* allergy to gabapentin
* history of developmental delay
Circadian Ocular Perfusion Pressure and Ocular Blood Flow

The purpose of this study was to compare the short term effects of two intraocular pressure (IOP) lowering medications on ocular perfusion pressure (OPP), ocular blood flow, intraocular pressure, and blood pressure in patients with glaucoma. Ocular perfusion pressure (OPP) is defined as the difference between arterial blood pressure (diastolic and systolic) and intraocular pressure. The primary efficacy assessment is based on diastolic ocular perfusion pressure.


Eligibility Criteria:
Inclusion Criteria:

* Sign Informed Consent.
* Diagnosis of open-angle glaucoma in at least one eye.
* Requires more than one IOP-lowering medication.
* IOP measurements at Screening, Safety, and Eligibility/Period 1 Baseline Visits as specified in protocol.
* Able to discontinue all IOP-lowering medication prior to Eligibility Visit and for 4 weeks between treatment periods.
* Willing to complete all required study visits.
* Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Female of child-bearing potential if pregnant, lactating, or not using highly effective birth control measures.
* Severe central visual field loss in either eye.
* Previous glaucoma surgery in the study eye.
* Intraocular surgery in the study eye within 3 months prior to the Screening Visit.
* Wears contact lenses.
* Allergy/hypersensitivity to study medication.
* Cannot safely discontinue use of glucocorticoid medication.
* Uses medication that could affect IOP or blood pressure.
* Recent use of high-dose aspirin.
* Bronchial asthma or severe chronic obstructive pulmonary disease.
* Diabetic retinopathy.
* Any abnormality preventing reliable tonometry.
* Any severe illness or condition unsuitable for the study, in the opinion of the investigator.
* Other protocol-defined exclusion criteria may apply.
Screening for Pregnancy Related Heart Failure in Nigeria

This study will evaluate the effectiveness of an artificial intelligence-enabled ECG (AI-ECG) for cardiomyopathy detection in an obstetric population in Nigeria.


Eligibility Criteria:
Inclusion Criteria:

* Currently pregnant or within 12 months postpartum
* Willing and able to provide informed consent

Exclusion Criteria:

* Complex congenital heart disease (single ventricle physiology or significant shunts with cardiac structural changes)
* Significant conduction abnormalities (ventricular pacing on recorded ECG, pacemaker dependence, or severely abnormal/bizarre QRS morphology on ECG tracings)
* Unable or unwilling to provide consent
Selective Thromboembolism Prophylaxis After Arthroplasty

Asian populations have a lower rate of high-risk gene mutations of venous thrombosis, which means a reasonable perioperative anticoagulant management after hip or knee arthroplasty for Caucasian populations may be too excessive for Asians. So, individual patient risk assessment, rather than a "blanket policy", is considered the best thromboembolism prophylaxis for Asians.The purpose of this study was to evaluate the effectiveness and safety of selective thromboembolism prophylaxis compared with conventional thromboembolism prophylaxis by risk stratification with thromboelastography (TEG) after joint arthroplasty for Asian populations.

Asian patients who underwent hip or knee arthroplasty in Guangdong General Hospital from August 2016 to August 2017 were randomly divided into selective anticoagulation group (SAG) and conventional anticoagulation group (CAG). SAG used anticoagulant when TEG indicated hypercoagulability while CAP used anticoagulant until one month after surgery regularly. Data including patients' basic information, postoperative complications, perioperative clotting index, intraoperative blood loss, perioperative TEG, volume of drainage, and blood transfusion were evaluated.

Eligibility Criteria:
Inclusion Criteria:

* over 18 years of age,
* ASA Ⅰ-Ⅱ grade,
* BMI \<40Kg / M \^ 2
* Underwent total knee arthroplasty/ total hip arthroplasty in Guangdong General Hospital
* consent to enroll in this study

Exclusion Criteria:

* history of VTE, preoperative infection, preoperative coagulation
* liver and kidney function existed clinically abnormalities
* history of tumor
* history of vascular surgery
* heart infarction or cerebral infarction within 6 months
* history of lower extremity surgery within 3 months
Prevalence, Management and Follow-up of Patients With Addiction to Opioid Analgesics

The demand for addiction care for patients with addiction to analgesics increases with the number of prescription of analgesics grade 2; this is a public health problem There is no support for repositories to date in the context of addiction analgesics grade 2.

Risk factors of misuse as well as diagnostic tools were identified.

The demand for addiction care for patients with addiction to analgesics increases with the number of prescription of analgesics grade 2; this is a public health problem There is no support for repositories to date in the context of addiction analgesics grade 2.

Risk factors of misuse as well as diagnostic tools were identified. The objectives of our research are to determine the characteristics of the individuals suffering from an addiction to analgesics of level 2 followed in consultation of addictology in the hospital of Montpellier and Nimes and to describe the type of follow-up proposed to the patients in these two centers. It is a retrospective and descriptive study.

As part of this research, we will solicit all the patients followed in consultation of addictology or in hospitalization to the hospital of Montpellier or Nîmes for an addiction to the analgesics of grade 2 between the 1st of January 2014 and the 10th of July 2017 with requests of management for withdrawal or reduction of doses, opioid analgesics in the absence of pain or in chronic non-cancer pain, opioid analgesics to avoid withdrawal syndrome or hyperalgesia and consumptions chronic to dosages inadequate to the functional complaint evaluated by the rhumatology or algology services.

The data are collected in the medical file at the two participating institutions (Montpellier and Nîmes) and if necessary, patients not seen in consultation for more than 6 months will be recontacted.

Eligibility Criteria:
Inclusion Criteria:

* Requests for management for weaning or reduction of doses
* Take opioid analgesics in the absence of pain or as part of chronic non-cancer pain
* Opioid analgesics to prevent withdrawal syndrome or hyperalgesia
* Chronic consumption at inadequate dosages compared to the functional complaint evaluated by the MPR / Algologie services
* Patients over 18 years and who agree with the study

Exclusion criteria:

* language barrier
* severe cognitive and / or psychiatric disorders
Liver Steatosis and Stiffness in HIV

Background:

With the advances in treatment and clinical care, individuals with human immunodeficiency virus (HIV) infection have experienced an increase in life expectancy. Liver disease is common among HIV-infected patients due to the shared routes of transmission of HIV and viral hepatitis. Nonalcoholic fatty liver disease (NAFLD) is the most common cause of elevated aminotransferases in HIV-monoinfected adults without HBV or HCV.

Vibration-controlled transient elastography (VCTE) has been shown to have good sensitivity and specificity for assessment of liver fibrosis in HIV and viral hepatitis coinfected patients, as well as in HIV-negative NASH population. Controlled attenuation parameter (CAP), a novel physical parameter developed using the postulate that fat affects ultrasound propagation, measures the ultrasound attenuation at the center frequency of the FibroScan®.

Study design:

This is a prospective observational study.

Objective:

The aim of this study is to evaluate the liver steatosis and fibrosis in HIV-infected patients by noninvasive methods of VCTE and CAP.

Methods:

Patient number: 200

Inclusion criteria:

1. Age: 20-65 years
2. Males and females with HIV infection diagnosed by infection doctors
3. Willing and able to comply with the study requirements
4. Willing and able to provide written informed consent to participate in the study

Exclusion criteria:

1. Pregnancy
2. Unable to complete the noninvasive procedure of VCTE and CAP
3. Unwilling to provide written informed consent to participate in the study


Eligibility Criteria:
Inclusion Criteria:

1. Age: 20-65 years
2. Males and females with HIV infection diagnosed by infection doctors
3. Willing and able to comply with the study requirements
4. Willing and able to provide written informed consent to participate in the study

Exclusion Criteria:

1. Pregnancy
2. Unable to complete the noninvasive procedure of VCTE and CAP
3. Unwilling to provide written informed consent to participate in the study
A Comparison of Clinical Simulation and Classical Learning for Airway Management in Medical Students

Multiple studies have shown clinical simulation benefits over classical learning method. Research on simulation of airway management has focused on endotracheal intubation training, while research on ventilation via facemask is scant. The investigators compared both learning methods regarding the acquirement of basic skills for airway management by medical students. Students in the clinical simulation group received a 3-hour training on airway management on the first day of their 28-day anesthesia rotation, while classical learning did not. On the last day of rotation, participants were evaluated based on a validated instrument of scores. Primary outcome was airway management scores. Secondary outcomes were rate of success of intubation and incidence of complications.


Eligibility Criteria:
Inclusion Criteria:

* Last year medical students at Universidad de los Andes
* Over 18 year old

Exclusion Criteria:

* Previous elective anesthesia rotation
* Motor deficit affecting the upper limbs
Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC

This study were designed to verify the better method of survival for metastatic ICC. Since the traditional method for metastatic ICC was GEMOX(first-line treatment from NCCN guideline), our previous study found similar results from FOLFOX (second-line treatment from NCCN guideline) compared with GEMOX.

Our current study were conducted for further investigation to verify the better method for metastatic ICC.

ICC(Intrahepatic CholangioCarcinoma) patients with metastasis has a short survival time and poor prognosis after diagnosis. Treatment methods was few and far from satisfaction. The treatment recommended from NCCN guideline was GEMOX(Systemic Chemotheray) and clinical trials. Our previous study has demonstrate FOLFOX (Systemic Chemotheray based on Oxaliplatin#5- fluorouracil) has a similar survival and tumor response compared with GEMOX. Further study was needed to intensive confirmation of the result. We designed this study to demonstrate the hypothesis. Metastasis ICCs were recruited and screened by our criteria. All patients were treated with FOLFOX (Systemic Chemotheray based on Oxaliplatin#5-fluorouracil ), apatinib (one of tyrosine kinase inhibitors) plus sintilimab (one of PD-1 antibody).

Our study were designed to verify the better method of survival for metastatic ICC.

Eligibility Criteria:
Inclusion Criteria:

* The diagnosis of ICC
* With distant metastasis
* Patients must have at least one tumor lesion that can be accurately measured according to mRECIST criteria.
* With no previous treatment
* No Cirrhosis or cirrhotic status of Child-Pugh class A only
* Not amendable to surgical resection ,local ablative therapy and any other cured treatment
* The following laboratory parameters:

Platelet count ≥ 60,000/μL Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 30mmol/ L Serum albumin ≥ 32 g/L ASL and AST ≤ 6 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of normal INR ≤ 1.5 or PT/APTT within normal limits Absolute neutrophil count (ANC) \>1,500/mm3

Exclusion Criteria:

* Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy
* Known history of HIV
* History of organ allograft
* Known or suspected allergy to the investigational agents or any agent given in association with this trial.
* Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
* Evidence of bleeding diathesis.
* Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.
Expanded Access for Single Patient Treatment of Autologous Human Schwann Cells (ahSC) for Peripheral Nerve Repair

The primary purpose of this research study is to determine the safety of injecting ones own Schwann cells as a supplement along with nerve autograft (eg sural nerve) a few weeks after a severe injury to the sciatic nerve has occurred.

The secondary purpose of this research project is to evaluate whether transplanted Schwann cells can enhance recovery of sensory and motor function. Emergency expanded access for a single patient was granted, as the patient was an ideal candidate for sural nerve repair augmented by autologous Schwann cells which could be harvested either from a relatively small segment of sensory nerve or as in this case from local debridement of injured nerve at the epicenter of the nerve injury. The cells were expanded using cell culture techniques and placed along with the sural nerve grafts wrapped by an FDA approved collagen matrix (Duragen). This study is being conducted at the Jackson Memorial and the University of Miami health systems. As a research subject the patient will be in this study for a total of 5 years from the date receiving Schwann cell transplant augmentation of sural nerve autografts.

Eligibility Criteria:
- single patient with severe sciatic nerve injury enrolled under emergency request
PC Protocol: Preconceptional Screening

Background: Despite considerable progress in the field of assisted reproductive technology (ART) maximum pregnancy rates generally do not exceed 30%. Furthermore, substantial differences in pregnancy rates are seen between women starting ART from seemingly similar clinical starting points and information on pregnancy/neonatal complications after ART is limited. For physicians and patients it would be extremely valuable if tools could be developed through which individualised chances of live birth and the development of pregnancy/neonatal complications can be calculated. In addition, there is increasing knowledge about health risks associated with subfertility and in particular with polycystic ovarian syndrome (PCOS) and premature ovarian failure (POF). An important void in research to date is the absence of a control group to check important new findings.

Objectives: The study protocol aims to form a cohort of normo-ovulatory women with a regular indication for ART which can aid the investigators principle lines of research:

1. To study initial predictors of ovarian response to stimulation for IVF
2. To study predictors of chances for live birth after repeated IVF cycles
3. To assess the role for vascular health in the probabilities of success in ART treatment
4. To study predictors for pregnancy and neonatal complications
5. To form a control group for cycle disturbance studies

Study design: In this part of the protocol, serum and material for DNA analysis will be collected by asking patients to have 20 ml of blood drawn during a routine blood withdrawal. This blood will be stored in the Biobank of the UMC Utrecht at -80 C.

Study population: All women starting ART will be asked to participate. Women starting donorinsemination treatment will be asked to participate, from the viewpoint that they potentially will form a normal fertile control group.

Nature and extent of the burden and benefits associated with participation: There are no benefits or risks for the study patient as blood is withdrawn during a routine venapuncture and results will not be used for clinical practice.

The aim of this protocol is to collect serum and genotype from normo-ovulatory women with a regular indication for IVF/ICSI that can aid further research into the investigators principle lines of research which include improving performance ART treatment , limiting pregnancy complications, and improving offspring health.

Eligibility Criteria:
Inclusion Criteria:

* normo-ovulatory with a regular indication for ART or undergoing donorinsemination

Exclusion Criteria:

* Women with cycle disturbances
Comparing Aloe Vera Gel and Rosemary Oil in Pressure Injury Prevention

Most patients admitted to the orthopedic ward are at risk of developing pressure ulcers. Today, the tendency to use medicinal herbs in pressure ulcer treatment has increased due to the variety of effective compounds and their fewer side effects.

Aloe Vera is medicinal plant that has been used to treat skin problems since 1500 BC Many studies have shown that using Aloe Vera to treat various wounds such as psoriasis, mouth ulcers, diabetic ulcers herpes and bed sores has had positive effects. in addition, Rosemary has therapeutic properties and has been used in the folk medicine, pharmaceutical, and cosmetics industries, mainly for its antioxidant, anti-inflammatory and vasodilatation properties, which are attributed to the presence of carnosol/carnosic and ursolic acids. Besides it therapeutic uses, rosemary has potential applications in cosmetic formulations and in the treatment of pathological and non-pathological conditions, such as cellulite, alopecia, ultraviolet damage, and aging.

Eligibility Criteria:
Inclusion Criteria:

* willingness to participate in research, lack of skin diseases (such as psoriasis, fungal illness, freckles), patients that are at risk of moderate to severe bedsores according to nursing diagnosis and Braden scoring tool and scored less than 13-14; the absence of PI on admission; the probability of length of stay should be above 10 days

Exclusion Criteria:

* a decrease in hemoglobin levels during the study to lower than 12 in men and less than 10 mg/dl in women, anemia, hyperthermia during the study and sensitivity to Aloe Vera or Rosemary.
The Utility of Platelet Rich Plasma in Hair Loss

Platelet rich plasma (PRP) is an autologous preparation of human plasma with high concentration of platelets. Platelets release numerous growth factors, which stimulate cell proliferation and differentiation.

The purpose of this research is to investigate the potential of PRP injection for treatment of hair loss. Clinical outcomes will be assessed by noninvasive techniques including dermoscopy, multiphoton microscopy, optical coherence tomography, optical Doppler tomography and multispectral imaging.


Eligibility Criteria:
Inclusion Criteria:

* Over 18 years of age
* Ability to understand and carry out instructions
* Diagnosed with alopecia

Exclusion Criteria:

* Inability to understand and.or carry out instructions
* Pregnant women
* Use of any topical medication (such as minoxidil or any other solution for hair growth), oral medication (finasteride, dutasteride, or antiandrogens), laser therapy, or chemotherapy, within the preceding 4 weeks.
* Personal medical history of bleeding disorders
* Personal medical history of platelet dysfunction syndrome
* Anti-coagulation therapy or nonsteroidal anti-inflammatory drugs in the last 1 week.